title: BEAM+autologous stem cell transplantation in malignant lymphoma: 100 consecutive transplants in a single centre. Efficacy, toxicity and engraftment in relation to stem-cell source and previous treatment.
abstract: One hundred consecutive patients with malignant lymphoma treated with high-dose chemotherapy and autologous stem cell transplantation, followed at least 1 yr post-transplant, are reported, 68 with non-Hodgkin's lymphoma and 32 with Hodgkin's disease. At transplant, 23 patients were in first remission, 69 in later chemosensitive disease and 8 were chemotherapy resistant. Based on previous treatment and stem-cell source, the patients were subdivided into 3 cohorts: BMT1: bone-marrow harvest and transplant after > or =3 treatment regimens (38 patients); BMT2: bone marrow harvest and transplant after less than 3 treatment regimens (24 patients); PBSCT: peripheral-blood stem cell transplant (38 patients, 5 of these with CD34+ cell selected PBSC). The 4-yr survival and progression-free survival of all patients was 45 and 40%, respectively. Forty-one patients have died, 27 of lymphoma, evenly distributed in the cohorts. Fourteen treatment-related deaths occurred, 13 of these in the BMT1 cohort, significantly more than in the other cohorts (p=0.001). In univariate survival analysis cohort, age, disease status at transplant and number of previous treatment regimens were significant. In multivariate survival analysis cohort, age and sex were independently significant, women having a shorter survival. The patients transplanted with unselected PBSC had significantly shorter duration of pancytopenia and hospital stay than the otherwise comparable BMT2 patients, but their progression-free survival was identical. We confirm that high-dose therapy with autologous stem cell transplant from blood or bone marrow in not-too-heavily pretreated patients is a safe procedure but will cure only half the patients.
authors.affiliation: Department of Haematology, the Finsen Center, Rigshospitalet, Copenhagen, Denmark. geisler@rh.dk
authors.forename: C H
authors.initials: CH
authors.lastname: Geisler
authors.forename: M M
authors.initials: MM
authors.lastname: Hansen
authors.forename: N S
authors.initials: NS
authors.lastname: Andersen
authors.forename: P
authors.initials: P
authors.lastname: Brown
authors.forename: L D
authors.initials: LD
authors.lastname: Christensen
authors.forename: E
authors.initials: E
authors.lastname: Dickmeiss
authors.forename: J
authors.initials: J
authors.lastname: Ersbøll
authors.forename: J
authors.initials: J
authors.lastname: Myhre
authors.forename: M
authors.initials: M
authors.lastname: Hansen
authors.forename: B R
authors.initials: BR
authors.lastname: Juhl
authors.forename: B T
authors.initials: BT
authors.lastname: Mortensen
authors.forename: J
authors.initials: J
authors.lastname: Pedersen-Bjergaard
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D005260:Female; D006085:Graft Survival; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D014182:Transplantation, Autologous